This article is more than 5 years old. Information may no longer be current.

MINIject reduces IOP in first-in-human trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The MINIject device significantly reduced IOP in its first-in-human trial, according to a press release from iSTAR Medical.

The prospective, open, international, multicenter study showed implantation of the MINIject, a microinvasive glaucoma surgery device, in 25 patients with mild to moderate primary open-angle glaucoma resulted in an average 39% IOP reduction to a mean of 14.2 mm Hg at 6 months. Topical medication usage was able to be discontinued in 87.5% of patients, who remained medication-free at 6 months, the release said.

No serious ocular adverse events were recorded. Safety and performance of the device will continue to be monitored for up to 2 years.